Yan Li
Accountancy at Market St, San Jose, CA

2012015, Jun 14, 2012

Dec 12, 2011

13/323769

Yan LI - San Jose CA, US
Hao ZHONG - Milpitas CA, US

H03M 13/09, H03M 13/05, G06F 11/10, G06F 11/00

714704, 714807, 714773, 714E11004, 714E11035

Cross-decoding assists decoding of an otherwise uncorrectable error when decoding a desired page of a multi-level-cell technology flash memory. A solid-state disk (SSD) controller adjusts space allocated to redundancy respectively within various pages (e.g. upper, middle, and lower pages) such that the respective pages have respective effective Bit Error Rates (BER)s, optionally including cross-decoding, that approach one another. Alternatively the controller adjusts the allocation to equalize decoding time (or alternatively access time), optionally including decoding time (accessing time) accrued as a result of cross-decoding when there is an otherwise uncorrectable error. The adjusting is via (a) respective ratios between allocation for ECC redundancy and user data space, and/or (b) respective coding rates and/or coding techniques for each of the various pages. Alternatively the controller adjusts the allocation to maximize total usable capacity by allocating to redundancy and data for the various pages, assuming that cross-decoding is to be used.

7667004, Feb 23, 2010

Nov 26, 2003

10/723434

Pingyu Zhong - Mountain View CA, US
Peizhi Luo - Sunnyvale CA, US
Kevin C. Wang - San Francisco CA, US
Mark Hsieh - San Francisco CA, US
Yan Li - San Jose CA, US

Abmaxis, Inc. - Mountain View CA

C12P 21/08

5303881, 530350, 5303873

Methods are provided for designing and selecting antibodies against human antigens with high affinity and specificity in silico and in vitro. In some particular embodiments, methods are provided for designing and selecting humanized or fully human antibodies against vascular endothelial growth factor (VEGF) with high affinity and specificity. In another aspect of the invention, monoclonal antibodies against VEGF are provided. In particular, humanized or human anti-VEGF monoclonal antibodies are provided with ability to bind to human VEGF with high affinity, inhibit VEGF-induced proliferation of endothelial cells in vitro and inhibit VEGF-induced angiogenesis in vivo. These antibodies and their derivative can be used in a wide variety of applications such as diagnosis, prevention, and treatment of diseases such as cancer, AMD, diabetic retinopathy, and other diseases derived from pathological angiogenesis.

2013013, May 30, 2013

Mar 11, 2011

13/583617

Hao Zhong - Milpitas CA, US
Yan Li - San Jose CA, US
Radoslav Danilak - Cupertino CA, US
Earl T. Cohen - Oakland CA, US

LSI CORPORATION - Milpitas CA

G06F 11/10

714773

A Solid-State Disk (SSD) controller uses LDPC decoding to enable flash memory accesses with improved latency and/or error correction capabilities. With SLC flash memory having a BER less than a predetermined value, the SSD controller uses a 1-bit read (single read) hard-decision LDPC decoder to access the flash memory. If the hard-decision LDPC decoder detects an uncorrectable error, then the SSD controller uses a 1.5-bit read (two reads) erasure-decision LDPC decoder to access the flash memory. With flash memory having a raw BER between two other predetermined values, the SSD controller omits the use of the hard-decision LDPC decoder and uses only the erasure-decision LDPC decoder to access the flash memory. Variations of the SSD controller similarly access MLC flash memory. Some SSD controllers dynamically switch between hard-decision and erasure-based decoders based on dynamic decoder selection criteria.

2014008, Mar 20, 2014

Sep 15, 2012

13/620982

Yan LI - San Jose CA, US
Alexander HUBRIS - San Jose CA, US
Hao ZHONG - Milpitas CA, US

LSI CORPORATION - Milpitas CA

G06F 11/16

714773

An NVM controller measures cell damage for wear leveling in an NVM, thus improving performance, reliability, lifetime, and/or cost of a storage sub-system, such as an SSD. In a first aspect, the controller determines that an error reading a page of NVM was caused by cell damage and/or cell leakage. The controller reprograms and immediately reads back the page, detecting that the error was caused by cell damage if an error is detected during the immediate read. In a second aspect, the cell damage is tracked by updating cell damage counters for pages and/or blocks of NVM. In a third aspect, wear leveling is performed based at least in part upon measured cell damage for pages and/or blocks of NVM.

8188233, May 29, 2012

Feb 6, 2009

12/322861

Jon H. Condra - Doylestown PA, US
Rose M. Cubbon - Fanwood NJ, US
Holly A. Hammond - Telford PA, US
Timothy McCabe - Doylestown PA, US
Shilpa Pandit - Edison NJ, US
Laurence B. Peterson - Westfield NJ, US
Joseph C. Santoro - Belle Mead NJ, US
Ayesha Sitlani - Metuchen NJ, US
Dana D. Wood - Collegeville PA, US
Henryk Mach - Ambler PA, US
Heidi Yoder - Glenside PA, US
Sonia M. Gregory - Blue Bell PA, US
Jeffrey T. Blue - Telford PA, US
Kevin Wang - Lansdale PA, US
Peter Luo - Lansdale PA, US
Denise K. Nawrocki - Annandale NJ, US
Pingyu Zhong - Blue Bell PA, US
Feng Dong - Lansdale PA, US
Yan Li - San Jose CA, US

Merck Sharp & Dohme Corp. - Rahway NJ

C07K 16/00, A61K 39/395, C12N 5/07, C12N 5/16

5303871, 4241301, 435326

Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

8188234, May 29, 2012

Feb 6, 2009

12/322867

Jon H. Condra - Doylestown PA, US
Rose M. Cubbon - Fanwood NJ, US
Holly A. Hammond - Telford PA, US
Laura Orsatti - Pomezia, IT
Shilpa Pandit - Edison NJ, US
Laurence B. Peterson - Westfield NJ, US
Joseph C. Santoro - Belle Mead NJ, US
Ayesha Sitlani - Metuchen NJ, US
Dana D. Wood - Collegeville PA, US
Henryk Mach - Ambler PA, US
Heidi Yoder - Glenside PA, US
Sonia M. Gregory - Blue Bell PA, US
Jeffrey T. Blue - Telford PA, US
Kevin Wang - Lansdale PA, US
Peter Luo - Lansdale PA, US
Denise K. Nawrocki - Annandale NJ, US
Pingyu Zhong - Blue Bell PA, US
Feng Dong - Lansdale PA, US
Yan Li - San Jose CA, US

Merck Sharp & Dohme Corp. - Rahway NJ

C07K 16/00, A61K 39/395, C12N 5/07, C12N 5/16

5303871, 4241301, 435326

Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

2012030, Nov 29, 2012

May 8, 2012

13/466439

Jon H. Condra - Doylestown PA, US
Rose M. Cubbon - Fanwood NJ, US
Holly A. Hammond - Telford PA, US
Laura Orsatti - Ponezia, IT
Shilpa Pandit - Edison NJ, US
Laurence B. Peterson - Westfield NJ, US
Joseph C. Santoro - Belle Mead NJ, US
Ayesha Sitlani - Metuchen MA, US
Dana D. Wood - Collegeville PA, US
Henryk Mach - Amber PA, US
Heidi Yoder - Glenside PA, US
Sonia M. Gregory - Charlottesville VA, US
Jeffrey T. Blue - Telford PA, US
Kevin Wang - Lansdale PA, US
Peizhi (Peter) Luo - Lansdale PA, US
Denise K. Nawrocki - Annandale NJ, US
Pingyu Zhong - Blue Bell PA, US
Feng Dong - Lansdale PA, US
Yan Li - San Jose CA, US

C07K 16/40, C12N 15/13, C12N 1/21, A61P 9/00, C12N 7/01, C12N 5/10, C12P 21/00, A61K 39/395, C12N 1/19

4241331, 5303873, 5303891, 536 2353, 4353201, 43525233, 43525231, 43525235, 4352542, 4352351, 435325, 435 696

Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

2012021, Aug 23, 2012

Oct 29, 2010

13/503729

Peter Peizhi Luo - Lansdale PA, US
Pingyu Zhong - Blue Bell PA, US
Mark Hsieh - Jenkintown PA, US
Yan Li - San Jose CA, US
Xinwei Wang - Germantown MD, US
Feng Dong - Lansdale PA, US
Andrei Golosov - Cambridge MA, US
Yan Ni - Westfield NJ, US
Weirong Wang - Harleysville PA, US
Laurence B. Peterson - Westfield NJ, US
Rose Cubbon - Fanwood NJ, US
Sujata Sharma - Eagleville PA, US
Jon Condra - Doylestown PA, US
Jun Lu - Lansdale PA, US
Gopalakrishnan Parthasarathy - Hillsborough NJ, US
Stephen Soisson - Hillsborough NJ, US
Noel Byrne - Doylestown PA, US

A61K 39/395, C12N 15/13, C12P 21/02, A61P 3/06, C12N 5/10, C12N 1/19, C12N 1/21, C07K 16/40, C12N 15/63

4241461, 53038826, 536 2353, 435 696, 4353201, 435338, 43525423, 435419, 43525233, 43525231, 43525235

Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

8030469, Oct 4, 2011

Nov 3, 2008

12/263919

Teikichi Aoyagi - Saitama, JP
Peter Peizhi Luo - Lansdale PA, US
Pingyu Zhong - Blue Bell PA, US
Mark Hsieh - Jenkintown PA, US
Yan Li - San Jose CA, US
Kevin Caili Wang - Lansdale PA, US
Chikao Morimoto - Setagaya-ku, JP

SBI Incubation Co., Ltd. - Tokyo

C07H 21/02, C07H 21/04, A61K 39/395, A61K 39/00

536 2353, 536 231, 4241301, 4241331, 4241581, 4241721

The present invention provides novel anti-CD26 antibodies and other, related polypeptides, as well as novel polynucleotides encoding the antibodies and polypeptides. The invention also provides methods of making the antibodies and polypeptides. Compositions and cells comprising the antibodies or polypeptides are further provided. Methods of using the antibodies and/or polypeptides, such as to inhibit cell proliferation and in the treatment of conditions associated with CD26, are also provided.